23:23:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.

Kalender

2023-04-17 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50
2021-12-15 16:35:07
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL
ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.

SoftOx Solutions AS (the "Company") has engaged SpareBank 1 Markets AS (the
"Manager"), to advise on and effect a contemplated private placement of up to
915,000 new shares (the "New Shares") in the Company (the "Private Placement").

The net proceeds from the Private Placement will be used to fund commercial
activities related to bringing the Hand Disinfection and Wound Irrigation
Solution to the European and the US market as well as finalization of phase 1
development of the Infection Remover (BE) and general corporate purposes.

The final subscription price per New Share (the "Subscription Price") and the
final number of New Shares to be issued, and as such, the total gross proceeds
from the Private Placement, will be determined through an accelerated book
building process. The Private Placement will be directed towards a limited
number of selected investors, in each case, subject to and in compliance with
applicable exemptions from relevant prospectus, filing and registration
requirements. The minimum application and allocation amount have been set to the
NOK equivalent of EUR 100,000. The Company may however, at its sole discretion,
allocate an amount below the NOK equivalent of EUR 100,000 to the extent
applicable exemptions from the prospectus requirement pursuant to applicable
regulations, including Regulation (EU) 2017/1129 and ancillary regulations, are
available.

The bookbuilding period for the Private Placement starts on 15 December at 16:30
hours (CET) and closes on 16 December 2021 at 08:00 hours (CET) (the
"Application Period"). The Company, together with the Manager, reserves the
right, at its own discretion, to extend or shorten the Application Period or
modify the terms of or cancel the Private Placement at any time (prior to
completion) and for any reason and on short notice. The allocation of New Shares
will be determined following the expiry of the Application Period and the final
allocation will be made by the board of directors of the Company. Notification
of allocation and payment instructions is expected to be issued to the
applicants on or about 16 December 2021 through an allocation letter to be
issued by the Manager (the "Notification").

The allocated New Shares in the Private Placement will be delivered to the
applicant's VPS account on a delivery versus payment (DVP) basis. Settlement for
the New Shares is expected to be on or about 20 December 2021. The New Shares
will be settled by delivery of existing and unencumbered shares in the Company
that are already traded on Euronext Growth Oslo to be lent from Dinge Invest AS
(the "Share Lender") by the Manager pursuant to a share lending agreement
between the Manager, the Company and the Share Lender (the "Share Loan"). The
allocated New Shares will be delivered to the applicant's VPS account as soon as
practicable after full payment has been received and the Conditions (as defined
below) for the Private Placement have been met. The Manager will settle the
Share Loan with new shares in the Company to be resolved issued by the board of
directors pursuant to the Board Authorization (as defined below).

Completion of the Private Placement is subject to the following conditions (the
"Conditions"): (i) the board resolving to consummate the Private Placement,
allocate the New Shares and issue the New Shares pursuant to the authorization
to increase the share capital of the Company granted by the Company's annual
general meeting of 13 April 2021 (the "Board Authorization"), (ii) the share
capital increase pertaining to the issuance of the allocated New Shares being
validly registered with the Norwegian Register of Business Enterprises and the
allocated New Shares being validly issued and registered in the VPS, and (iii)
the Share Lending Agreement not being terminated prior to allocation.

Almhaug Bolig AS has, in connection with the Private Placement, exercised its
right to convert NOK 10 million of its short-term unsecured interest-free NOK 15
million loan to the Company, into new shares in the Company at a conversion
price of NOK 38.55 per share in accordance with the loan agreement between the
Company and Almhaug Bolig AS dated 13 October 2021 (the "Debt Conversion"). The
subscription price per share was set based on the volume weighted average share
price in the period before the loan was granted. The Debt Conversion is subject
to completion of the Private Placement and the resolution by the Company's
extraordinary general meeting to issue the new shares in a share capital
increase by way of conversion of debt, which is expected to be held on or about
29 December 2021.

The Private Placement represents a deviation from the shareholders' pre-emptive
right to subscribe for the New Shares. The board of directors has considered the
Private Placement in light of the equal treatment obligations under the
Norwegian Securities Trading Act and the rules of equal treatment set out in the
continuing obligations for companies admitted to trading on Euronext Growth and
Oslo Børs' guidelines on the rules of equal treatment, and has concluded that
there is a basis for deviating from the existing shareholders' preferential
rights. The board of directors has in this respect, inter alia, taken into
consideration (i) that the Company needs funding to pursue its growth strategy
and that the Private Placement allows the Company to utilize the current trading
prices of the shares and favourable market conditions, in particular in light of
the volatility in the Company's shares